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Abstract: In this study, we demonstrate the concept of
“topology-matching design” for virus inhibitors. With the
current knowledge of influenza A virus (IAV), we designed
a nanoparticle-based inhibitor (nano-inhibitor) that has
a matched nanotopology to IAV virions and shows hetero-
multivalent inhibitory effects on hemagglutinin and neurami-
nidase. The synthesized nano-inhibitor can neutralize the viral
particle extracellularly and block its attachment and entry to
the host cells. The virus replication was significantly reduced by
6 orders of magnitude in the presence of the reverse designed
nano-inhibitors. Even when used 24 hours after the infection,
more than 99.999% inhibition is still achieved, which indicates
such a nano-inhibitor might be a potent antiviral for the
treatment of influenza infection.
Besides the recent SARS-CoV-2 pandemic, outbreaks of
seasonal or pandemic influenza A virus (IAV) have also
challenged public health due to the high mutation rates of
viral glycoprotein genes and the potential for human infection
by animal strains.[1] Due to the lack of universal influenza
vaccines, a robust virus-neutralizing therapeutic is needed.[2]
IAV is an enveloped RNA virus, the membrane of which
anchors two viral proteins that regulate interactions of the
virion with the host cells, hemagglutinin (HA) and neurami-
nidase (NA).[3] For infection, IAV uses HA to bind to sialic
acid on the host cell membrane. After completion of the
replication cycle, the viral NA cleaves sialic acid from surface
receptors to allow virion release, so-called budding.[4] Recent
evidence also demonstrates that NA helps IAV penetration in
the mucus by cleaving HA decoy receptors, which reveals the
crucial role for a balanced HA/NA interplay for the binding
behavior.[5] Multivalent sialylated nanostructures have been
developed to inhibit HA and block viral entry to host cells.[6]
However, heteromultivalent inhibitors engaging both HA
and NA have been rarely been reported.[15]
From a topological viewpoint, the virion of IAV is nano-
sized particle around 100 nm with a spiky surface generated
by the HA and NA.[7] For an inhibitor, especially nano-
particle-based inhibitors (nano-inhibitors), matching the size
and topology to the virion is essential in order to achieve
robust binding to compete with the virus/cell interaction. For
this purpose, flexible nanomaterials are favored to afford the
viral binding ligands, but they also face the problem of
overcoming the internal stress of the scaffold nanomaterials.[8]
In our new approach, we used a rigid nanoparticle with
a matching nanotopology to the viral particle, which binds
more strongly than the flexible nanomaterials.[9]
The aim of this study was to develop a nano-inhibitor with
the principle of topology-matching design. The inhibitor
should not only show dual inhibitory effects on HA and NA,
but should also exhibit a matched nanotopology to IAV
virion, which is expected to increase the contact area and
enhance the binding. To achieve that, a virus-like nanoparticle
(VLNP) with nanospikes was first synthesized according to an
earlier report.[10] Except for the difference of the morphology,
the VLNP was the same as its smooth control nanoparticle for
size and density (Figure S2 in the Supporting Information).
Then, the nano-inhibitor was synthesized through the func-
tionalization of the VLNP with linear polyglycerol-sialyllac-
tose (LPG-SAL) and LPG-zanamivir (LPG-Zan) through
copper-free SPAAC click reactions as shown in Figure 1a.
Despite the different subtypes of HA, human IAV strains
tend to bind the 6’-sialyllactose for entry into host cells.[11] In
this study, 6’-sialyllactose was conjugated onto the nano-
particles via an LPG linker in a multivalent manner as shown
in Figure 1b, since polyglycerol-based multivalent structures
have been shown to efficiently to block virus infection in our
former studies.[6c,d] In order to inhibit NA, an approved NA
inhibitor, zanamivir, was also conjugated to the VLNPs,
similarly in a multivalent manner.[12] The resulted hetero-
multivalent structure is expected to bind IAV virion strongly
as shown in Figure 1 c.
High-resolution TEM (HR-TEM) images were acquired
to show the LPG-SAL and LPG-Zan conjugation on the
VLNPs (Figure 1d). The bare VLNPs had a rough surface
with clear and sharp edges. With the conjugation of LPG-SAL
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and LPG-Zan, the spiky nanostructure is smoother, but
a rough surface was still noticed, which shows advantages for
the efficient binding of virus in the following studies. The
chemical structure of VLNP-SAL/Zan was studied by XPS
analysis, as shown in Figure 1e,f. From the XPS N1s scan, the
emerge of the N1s signal for VLNP-SAL/Zan indicated that
the LPG-SAL and LPG-Zan have been conjugated to the
VLNP. For the N1s scan, three characteristic peaks were
detected as shown in Figure 1e. Overall, the results of HR-
TEM and XPS revealed that the VLNPs had been success-
fully functionalized with LPG-SAL and LPG-Zan.
Binding with the virus was studied by a centrifuge western
blotting as shown in Figure 2a,b and Figure S4, and the band
intensity for the viral nucleoprotein (viral NP) reveals the
amounts of virus binding to the nanoparticles. For the LPG-
functionalized smooth nanoparticles (Figure S4), no binding
was detected. But VLNP-LPG showed weak binding with the
virus, which is likely due to the spiky nanostructures on the
surface. All the SAL nanoparticles showed robust binding to
influenza virus and VLNP-SAL/Zan was better than VLNP-
SAL. This should be attributed to the additional interactions
between Zan and NA, which not only added extra binding
sites to the nanoparticles, but also enhanced the SAL/HA
interaction.[13] It was also clear that the nanospikes on the
surface have a positive effect on the viral binding. Cryo-TEM
image was acquired to show the effect of the nanospikes on
the viral binding as shown in Figure 2c. From the images, it
can be seen that the surface proteins can insert into the gaps
of the nanospikes, which increased the contact area to benefit
the binding. Furthermore, aggregates of the VLNP-SAL/Zan
with the virus particles were also noticed.
NA inhibition was stud-
ied by MU-NANA assay
(Figure 2d). The nanoparti-
cles with zanamivir all
showed inhibition of NA
and the IC50(NA) values for
the VLNP-SAL/Zan, NP-
SAL/Zan, and VLNP-Zan
particles are 5.38 1.37,
40.34 10.82, 20.54
1.31 mg mL1, respectively.
By comparing the results for
VLNP-SAL/Zan and NP-
SAL/Zan, an enhancement
by a factor of 8 was also
noticed for the spiky nano-
structures, which can be
attributed to increased virus
binding by the spiky nano-
structures.
We then investigated
whether the binding of IAV
virions to MDCK II cells can
be blocked by the nano-
inhibitors, to demonstrate
that they act through a bind-
ing-decoy mechanism (Fig-
ure 3a–c). In this test, virions
of influenza A/X31 (H3N2) were labelled with octadecyl
rhodamine B chloride (R18) and incubated with the nano-
inhibitors for 45 minutes.[14] After being incubated for
45 minutes with the virion/inhibitor mixture, the cells were
washed with PBS to remove free virus and then fixed for
fluorescent microscopy (Figure 3a) or harvested for flow
cytometry (Figure 3b). The results clearly show that the
number of virions binding to the cells was reduced by the
Figure 1. a) Synthetic outline for the topology-matching design of nano-inhibitors towards IAV. b) Structure of
LPG-SAL-N3 and LPG-Zan-N3, which were used for the functionalization. Detailed structures are shown
Figure S1. c) Proposed binding patterns between VLNP-SAL/Zan and influenza virus particles. d) HR-TEM
images for the VLNPs before and after the functionalization. Scale bar: 100 nm. The images for smooth
nanoparticle are shown in Figure S3. e) XPS N1s spectra for the VLNPs with the functionalization. f) Peak
analysis for the XPS N1s spectra for VLNP-SAL/Zan.
Figure 2. a) Western blot of influenza nucleoprotein (NP) that reveals
viral binding to the nanoparticles.b) Band-intensity analysis for the
western blot in (a). c) Cryo-EM images for virus binding to VLNP-SAL/
Zan. The virus is marked yellow for a better view. Images without
marks are shown in Figure S5. Scale Bar: 100 nm. d) Inhibition of NA
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nano-inhibitors with SAL functionalization. For VLNP-SAL/
Zan, there was nearly no signal for virus being detected by
CLSM, and the fluorescence intensity profile for the cells was
identical to the no-virus control sample as shown in flow-
cytometry, which confirms our hypothesis that the spiky nano-
inhibitors can block virus binding to the host cells effectively.
With the proof of decoy binding, we then investigated
whether the nano-inhibitors could inhibit influenza virus
infection at the entry step. Immunofluorescence staining of
viral NP in the infected cells was carried out. All cells were
marked with the DAPI stain (blue) while the infected cells
were additionally marked by staining of the viral NP (pink) as
shown in Figure 3d,e. In control cultures, 42.2 6.6% of the
cells expressed viral antigen. Pre-treatment with the nano-
inhibitors clearly reduced infection. Without SAL or Zan,
there was no significant inhibition of viral infection, which
excludes an effect by underivatized LPG for the viral
inhibition (Figure S7). For the cells treated with VLNP-SAL
and VLNP-Zan, the infection rates were 6.2 2.8% and
22.5 2.9%, respectively. Few to no infected cells (0.1
0.1%) were detected upon treatment with VLNP-SAL/Zan,
which corresponds to an inhibition ratio higher than 99.9 %.
A potent influenza inhibitor should show robust inhib-
itory activity even when used after the infection. We
evaluated inhibition of post-infection viral replication by the
nano-inhibitors by using a multicyclic viral replication assay.
In this assay, MDCK II cells were infected with virus at
a multiplicity of infection
(MOI) of 0.01, and then
cultured in the medium sup-
plied with the nano-inhibi-
tors for 24 hours. Afterwards,
the active virus in the
medium was titrated by
plaque assay to investigate
viral replication. We first
investigated the inhibitory
effects on influenza A/X31
(H3N2) for the inhibitors at
different concentrations
from 50 to 1000 mgmL1
(Figure 4a). Potent inhibi-
tion with a reduction in viral




Zan at the cellular non-toxic
dose, which support a thera-
peutic window for the inhib-
itor. With only 50 mg mL1
VLNP-SAL, a reduction of
5 orders of magnitudes was
achieved. NP-SAL/Zan
showed potent inhibition at
high doses, but at 50 mgmL1,
the viral titre was reduced by
only 2.5 orders of magni-
tudes, thus supporting the
idea that the spiky nanostructures can enhance viral binding
and inhibition. Similar inhibitory effects were obtained for
infection with two other typical human IAV strains, A/PR/8/
34 (H1N1) and A/Panama/2007/1999 (H3N2), which indi-
cated that the VLNP-SAL/Zan might be broadly active in
human IAV strains (Figure 4 b).
We also evaluated inhibition of viral replication at a late
stage of infection with high viral load (Figure S9). In this case,
the nano-inhibitors were used 24 hours post infection. Com-
pared with the experimental settings for Figure 4a,b, there
were 2.5-fold more replication cycles, with approximately 108
PFUmL1 virions in the medium before using the inhibitors.
Reduction in viral titres was also achieved with VLNP-SAL/
Zan, for which a reduction of 5 orders of magnitudes was
achieved, which was slightly lower but in the same level as its
performance in the early-stage inhibition. However, in this
case, VLNP-SAL only showed a moderate inhibition of viral
replication, with a reduction of just 2 orders of magnitudes.
The potent inhibitory effects indicate that the viruses
might be neutralized by the nano-inhibitors in the medium.
For verification, plaque-reduction assays were carried out
(Figure 4c–e). Dose-dependent plaque reduction (PR) curves
were obtained by varying the nano-inhibitor concentrations
(Figure 4d) and the IC50 values were then estimated (Fig-
ure 4e). VLNP-SAL/Zan showed the best plaque reduction
performance, for which the IC50(PR) is 1.33 0.14 mg mL1. The
tendencies for VLNP-SAL and NP-SAL/Zan were similar to
Figure 3. a) Projection CLSM images for virion binding to MDCK II cells in the presence of the inhibitors.
Scale bar: 20 mm. b) Flow-cytometry analysis for the virion binding to MDCK II cells in the presence of VLNP-
SAL/Zan. c) Virus attachment analysis for the CLSM images and flow-cytometry results. Values are expressed
as meanSD, n = 4. d) Immunofluorescence staining of the viral NP to show the cellular infections at an
MOI of 1. Scale bar: 50 mm, MOI = multiplicity of infection. e) Inhibition ratios for the nano-inhibitors from
the counting of infected cells. Values are expressed as meanSD, n= 4. **p<0.01, ***p<0.001 by Student
t-test. Detailed data for other inhibitors are shown Figure S7 and S8.
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that for VLNP-SAL/Zan, but with higher IC50(PR) values. For
VLNP-Zan, only a slight reduction in viral activity was
noticed. This also indicates efficient neutralizing of the virus,
for which heteromultivalent engagement with both HA and
NA is essential.
In conclusion, in this study, we demonstrated the top-
ology-matching design of an IAV inhibitor that has a matching
surface topology towards the IAV particle and shows dual
inhibitory effects towards the two key proteins for viral
binding. The synthesized nano-inhibitor is able to neutralize
IAV virions extracellularly and block their binding to the host
cells. As a result, robust inhibition (> 99.9999% or a reduc-
tions of 6 orders of magnitude) of viral replication is achieved.
We also envision that the idea of topology-matching design
could be extended to the inhibition of other viruses, especially
ones with a spiky morphology such as coronaviruses.
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